{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.1","upperLimit":"20.5","value":"11.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"SDD will be reported as descriptive results as a median point estimate and a 90% confidence interval (CI) estimate.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months","title":"Stable Disease Duration (SDD)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}